Alnylam Pharmaceuticals (ALNY) Reports Initial Positive Top-Line Data From Phase 1 Clinical Trial With ALN-AT3, An Rnai Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)
5/13/2014 8:08:22 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase 1 trial of ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBD). These top-line results are being presented at the World Federation of Hemophilia (WFH) 2014 World Congress being held May 11 – 15, 2014 in Melbourne, Australia.
Help employers find you! Check out all the jobs and post your resume.
comments powered by